Competitive surface-blocking electrochemical sensor for fosfomycin detection based on ferrocen-tagged surface chemistry


Zouari M., Cetinkaya A., ÖZKAN S. A.

Microchimica Acta, vol.193, no.3, 2026 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 193 Issue: 3
  • Publication Date: 2026
  • Doi Number: 10.1007/s00604-026-07888-w
  • Journal Name: Microchimica Acta
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Chemical Abstracts Core, Chimica, Compendex
  • Keywords: Competitive surface-blocking assay, Ferrocen tag, Fosfomycin, Gold nanoparticles, Reduced graphene oxide, Screen-printed carbon electrode, Therapeutic drug monitoring
  • Ankara University Affiliated: Yes

Abstract

A disposable electrochemical sensor based on a competitive surface-blocking mechanism driven by covalent epoxide–amine coupling is reported for the selective voltammetric determination of fosfomycin (Fos). The sensing strategy employs ferrocen (Fc)-tagged surface chemistry as a redox reporter, where Fc surface occupancy inversely reflects Fos binding to cysteamine-derived amine groups. Screen-printed carbon electrodes (SPCEs) modified with a reduced graphene oxide/gold nanoparticle (rGO/AuNP) nanocomposite provide enhanced electroactive surface area and improved electron-transfer kinetics. Increasing Fos concentrations progressively consume surface amines, reducing Fc labeling and leading to a concentration-dependent decrease of the differential pulse voltammetric oxidation signal. Under optimized conditions, the sensor exhibits a linear response from 50 to 2000 µM with a limit of detection of 10 µM, matching the clinically relevant mid-therapeutic range of intravenous fosfomycin therapy (≈ 7–276 mg L⁻¹). Matrix effects are effectively minimized by controlled serum dilution, enabling accurate Fos quantification with recoveries of 97.8–103.7% and without extensive sample pretreatment. The platform retains stable performance for at least 15 days at 4 °C. Rather than replacing chromatographic techniques, this proof-of-concept platform is positioned as a rapid, low-cost, and portable electrochemical tool for routine therapeutic drug monitoring and point-of-care screening.